Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards

Moderna and Pfizer COVID-19 vaccines set a high bar for competitors

By Brian Buntz | November 16, 2020

Moderna

Moderna Logo (PRNewsFoto/Moderna Therapeutics)

Moderna (NSDQ:MRNA) is now the second company to release positive preliminary results from a Phase 3 trial of a COVID-19 vaccine candidate — and it appears to be more good news.

Last week, Pfizer (NYSE:PFE) announced that early data suggested its BNT162 mRNA-based vaccine was more than 90% effective at reducing symptomatic COVID-19 infections. 

Today, Moderna has announced interim analysis data suggesting its mRNA-1273 is 94.5% effective. 

FDA required that the vaccine have an efficacy rate of at least 50%. 

The Moderna and Pfizer vaccines could enter clinical use within weeks, said Michael Breen, director of infectious diseases and ophthalmology at GlobalData over email. The “path forward for other developers now remains unclear,” Breen said. The expectation that vaccines have an efficacy of 90% or greater could lead to an earlier-than-expected winnowing of the field. 

But there still could be an appetite for vaccines with inferior efficacy in some geographies as the Pfizer and Moderna vaccines may not be widely available internationally, leading some regions to “go with their best vaccine option at the time,” Breen said. 

In late morning trading, Pfizer shares tumbled nearly 4% while Moderna stock jumped 8.5%. 

Moderna’s vaccine uses an mRNA delivery platform with stabilized SARS-CoV-2 spike immunogen (S-2P).

Moderna’s Phase 3 COVE trial has more than 30,000 volunteers spread across 100 research sites in the U.S. The company launched the study on July 27.  

From that pool, at least 95 participants have contracted symptomatic COVID-19, with only five of those from the vaccinated arm. A total of 11 patients acquired severe COVID-19 from the placebo group, while no patients from the vaccinated pool did. 

The high efficacy rate could persuade the public to receive vaccines, according to Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases. In a Bloomberg interview on Nov. 14, Fauci said that Pfizer’s vaccine has “an extraordinarily high degree of efficacy — more than 90%, close to 95%.” 

On Monday, Health and Human Services Secretary Alex Azar told CNBC that FDA would move “as quickly as possible” to clear Moderna’s and Pfizer’s vaccines for emergency use.    

Pfizer hopes to produce 50 million vaccine doses by the end of this year and 1.3 billion in 2021. Moderna estimates that it can produce 500 million to 1 billion doses next year. 

Comments

  1. Ron says

    November 17, 2020 at 8:36 pm

    Informed consent disclosure to vaccine trial subjects of risk of COVID‐19 vaccines worsening clinical disease and destroy your immunity.

    Reply

Tell Us What You Think! Cancel reply

Related Articles Read More >

AstraZeneca-Oxford
Study finds AstraZeneca COVID-19 vaccine could be effective against Brazil variant
RCSB Protein Data Bank now has more than 1,000 SARS-CoV-2 proteins
Data sciencea
Q&A: Keys to unlock data science potential for drug discovery
Ivermectin not supported for mild COVID-19, study says

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Drug Discovery and Development
  • Enews Signup
  • Contact Us
  • R&D World
  • Pharmaceutical Processing
  • Drug Delivery Business News

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards